Natixis Advisors L.P. Has $30.18 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Natixis Advisors L.P. trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY) by 29.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 588,221 shares of the biopharmaceutical company’s stock after selling 251,441 shares during the quarter. Natixis Advisors L.P.’s holdings in Bristol-Myers Squibb were worth $30,181,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. OFI Invest Asset Management acquired a new stake in Bristol-Myers Squibb in the third quarter worth $25,000. Milestone Investment Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth about $27,000. Blue Bell Private Wealth Management LLC raised its stake in Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares in the last quarter. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $40,000. Finally, Wetzel Investment Advisors Inc. bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at approximately $40,000. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of Bristol-Myers Squibb stock opened at $43.99 on Friday. The firm has a market capitalization of $89.17 billion, a P/E ratio of -14.19, a PEG ratio of 14.82 and a beta of 0.45. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The company has a 50 day moving average price of $50.37 and a 200 day moving average price of $50.74. Bristol-Myers Squibb has a 52 week low of $43.33 and a 52 week high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.05 EPS. Sell-side analysts expect that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were paid a $0.60 dividend. The ex-dividend date of this dividend was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 5.46%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of research reports. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Barclays reduced their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Finally, StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.